The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Is multiple sclerosis a mitochondrial disease?
Open accessAbstract
Multiple sclerosis (MS) is a relatively common and etiologically unknown disease with no cure treatment. It is the leading cause of neurological disability in young adults, affecting over two million people worldwide. Traditionally, MS has been considered a chronic, inflammatory disorder of the central white matter in which ensuing demyelination results in physical disability. Recently, MS has become increasingly viewed as a neurodegenerative disorder in which axonal injury, neuronal loss, and atrophy of the central nervous system lead to permanent neurological and clinical disability. In this article, we discuss the latest developments on MS research, including etiology, pathology, genetic association, EAE animal models, mechanisms of neuronal injury and axonal transport and therapeutics. In this article, we also focus on the mechanisms of mitochondrial dysfunction that are involved in MS, including mitochondrial DNA defects, and mitochondrial structural/functional changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Oxidative Stress, Glutamate, and Neurodegenerative Disorders
Coyle, J. T., & Puttfarcken, P. (1993) · Science · doi:10.1126/science.7901908 · Cited by 3,762
Oxidative stress and neurodegeneration: where are we now?
Halliwell, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03907.x · Cited by 2,614
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280
Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 2×
“Recently, evidence for widespread axonal damage even at the earliest clinical stages of MS has been reported [51, 107] , leading to the hypothesis that MS is a neurodegenerative disorder in which axonal injury, neuronal loss, and atrophy of the CNS begin in the earliest stages of the disease and then intensify over ti…”
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., & Tsujimoto, Y. (2005) · Nature · doi:10.1038/nature03317 · Cited by 1,635 · cited 2×
“The PLP (139) (140) (141) (142) (143) (144) (145) (146) (147) (148) (149) (150) (151) MAPs were very efficient agents in preventing the development of clinical disease when administered after immunization.”
BackgroundRemyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
Oxidative Stress in Neurodegenerative Diseases
Simonian, N. A., & Coyle, J. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.000503 · Cited by 1,377 · cited 3×
“The PLP (139) (140) (141) (142) (143) (144) (145) (146) (147) (148) (149) (150) (151) MAPs were very efficient agents in preventing the development of clinical disease when administered after immunization.”
BackgroundDebris clearance by microglia: an essential link between degeneration and regeneration
Neumann, H., Kotter, M. R., & Franklin, R. J. M. (2008) · Brain · doi:10.1093/brain/awn109 · Cited by 1,111
Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052
Gold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017 · cited 2×
“To understand the disease progression and pathology of MS in mice, it is important to study multiple mouse models of EAE that may provide more human MS features [94] .”
BackgroundArchitecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927 · cited 1×
“Moreover, the production of superoxide occurs mostly within the mitochondria, mainly in complexes I and III, TCA cycle and conditionally in complex II [115, [118] [119] [120] [121] .”
BackgroundOffen, D., Gilgun-Sherki, Y., & Melamed, E. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0348-9 · Cited by 638
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621
Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 2×
“Notably remyelination is regulated by stimulators and inhibitors [69, 184, 200] .”
BackgroundSteinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Mitochondrial changes within axons in multiple sclerosis
Mahad, D. J., Ziabreva, I., Campbell, G., Lax, N., White, K., Hanson, P. S., Lassmann, H., & Turnbull, D. M. (2009) · Brain · doi:10.1093/brain/awp046 · Cited by 454
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis
Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347
Oligodendrocyte development and the onset of myelination in the human fetal brain
Jakovcevski, I. (2009) · Frontiers in Neuroanatomy · doi:10.3389/neuro.05.005.2009 · Cited by 323
Dada, L. A., Chandel, N. S., Ridge, K. M., Pedemonte, C., Bertorello, A. M., & Sznajder, J. I. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316826 · Cited by 314
Mi, S., Miller, R. H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C. B., Zhang, Y., Miklasz, S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21581 · Cited by 300 · cited 1×
“Therefore antagonism of LINGO-1 or its pathway is a promising approach for the treatment of MS [201, 202] .”
BackgroundMitochondrial Medicine for Aging and Neurodegenerative Diseases
Reddy, P. H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8044-z · Cited by 230 · cited 5×
“Mitochondria are not only the energy factory for cells but also the seat of a number of important cellular functions, including essential pathways of intermediate metabolism, amino acid biosynthesis, fatty acid oxidation, steroid metabolism, calcium handling and apoptosis [56, 114, 116, 117] .”
BackgroundInfluentialSelf-citationAutophagic Stress in Neuronal Injury and Disease
Chu, C. T. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000229233.75253.be · Cited by 211 · cited 1×
“However, excessive or imbalanced induction of autophagic recycling can actively contribute to neuronal atrophy, neurite degeneration, and cell death [72, 73, 76] .”
BackgroundReview: Mitochondria and disease progression in multiple sclerosis
Mahad, D., Lassmann, H., & Turnbull, D. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00987.x · Cited by 193
Preactive lesions in multiple sclerosis
van der Valk, P., & Amor, S. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832b4c76 · Cited by 156
Comabella, M., Craig, D. W., Camiña-Tato, M., Morcillo, C., Lopez, C., Navarro, A., Rio, J., BiomarkerMS Study Group, Montalban, X., & Martin, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003490 · Cited by 105
A Potential Role for Estrogen in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
OFFNER, H., & POLANCZYK, M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1386.021 · Cited by 102
Depression and multiple sclerosis: Review of a lethal combination
Wallin, M. T., Wilken, J. A., Turner, A. P., Williams, R. M., & Kane, R. (2006) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2004.09.0117 · Cited by 101
Vyshkina, T., Sylvester, A., Sadiq, S., Bonilla, E., Canter, J. A., Perl, A., & Kalman, B. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.011 · Cited by 90
Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328122de1b · Cited by 46
Cited by
Oxidative damage in multiple sclerosis lesions
Haider, L., Fischer, M. T., Frischer, J. M., Bauer, J., Hoftberger, R., Botond, G., Esterbauer, H., Binder, C. J., Witztum, J. L., & Lassmann, H. (2011) · Brain · doi:10.1093/brain/awr128 · Cited by 753
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas
Reiter, R. J., Rosales-Corral, S., Tan, D. X., Jou, M. J., Galano, A., & Xu, B. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2609-7 · Cited by 558
Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics
Tan, D.-X., Manchester, L., Qin, L., & Reiter, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122124 · Cited by 402
Gardner, A., & Boles, R. G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.030 · Cited by 333
Metadata
- Authors
- Mao, P., & Reddy, P. H.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 1802
- Issue
- 1
- Pages
- 66-79
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2118855202
- Cited by
- 243
- References
- 31
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.